Business, energy, technology, markets and global industry news from Business News Today

Nemluvio

PharmaDeviceNews Nemluvio
Representative image: A dermatologist examines chronic hand eczema as LEO Pharma’s ESCD 2026 data highlight the condition’s impact on work, school participation and daily life.
Pharma & Biotech

One antibody could target both eczema inflammation and itching. Zai Lab’s first human results are coming

Zai Lab will present initial Phase 1 data for ZL-1503 at ACAAI 2026 on November 13, evaluating safety, pharmacokinetics and inflammatory biomarkers in healthy volunteers. The investigational bispecific antibody targets IL-13 and IL-31 receptor signaling, but clinical efficacy in patients with atopic dermatitis remains unreported.

Read More
Representative image of a child undergoing a dermatology skin examination, illustrating the growing focus on pediatric eczema treatment as Galderma’s nemolizumab phase II data sharpen competition in the biologic landscape for atopic dermatitis.
Pharma & Biotech

Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?

Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?

Read More
A clinician examines atopic dermatitis symptoms as Bambusa Therapeutics reports preliminary proof-of-concept results for investigational bispecific antibody BBT001. Representative image.
Pharma & Biotech

Could BBT001 quarterly dosing differentiate Bambusa in the atopic dermatitis biologics market?

Bambusa’s BBT001 produced an early atopic dermatitis signal, but larger trials must confirm safety, durability and quarterly dosing.

Read More
Representative image of a child undergoing a dermatology skin examination, illustrating the growing focus on pediatric eczema treatment as Galderma’s nemolizumab phase II data sharpen competition in the biologic landscape for atopic dermatitis.
Pharma & Biotech

What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema

Galderma's nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.

Read More